Jazz Pharmaceuticals Plc

Health Care
Biotechnology: Pharmaceutical Preparations
www.jazzpharmaceuticals.com

Earnings Score
Moat Score
Safety Score

Market Cap $7.53B
PE 16
Debt $6.23B
Cash $2.22B
EV $11.54B
FCF $1.13B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$463.16M
EBIT	$657.14M
ROE	11%
ROA	5%
FCF	$1.13B
Equity	$4.17B
Growth Stability	-155%
PE	16.26
PEG	4.96
PB	1.8
P/FCF	6.66
P/S	1.89
Price/Cash	0.29
Debt/Equity	1.49
Debt/FCF	5.51
Net Margins	12%
Op. Margins	16%
Earnings CAGR	-2%
Sales Growth YoY	9%
Sales Growth QoQ	3%
Sales CAGR	15%
FCF CAGR	10%
Equity CAGR	11%
Earnings Stability	0.02
Earnings Growth YoY	46%
Earnings Growth QoQ	28%

Earnings CAGR 5Y	3%
Sales CAGR 5Y	16%
FCF CAGR 5Y	11%
Equity CAGR 5Y	3%
Earnings CAGR 3Y	8%
Sales CAGR 3Y	8%
FCF CAGR 3Y	14%
Equity CAGR 3Y	6%
Market Cap	$7.53B
Revenue	$3.99B
Assets	$12.26B
Total Debt	$6.23B
Cash	$2.22B
Shares Outstanding	61.41M
EV	11.54B
Earnings Score	6%
Moat Score	83%
Safety Score	50%
Final Score	46%
Working Capital	3.36B
Current Ratio	4.26
Shares Growth 3y	1%
Equity Growth QoQ	11%
Equity Growth YoY	20%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

SEC Filings

Direct access to Jazz Pharmaceuticals Plc (JAZZ) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Jazz Pharmaceuticals Plc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Jazz Pharmaceuticals Plc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -2%

Stability 2%

loading chart...

Jazz Pharmaceuticals Plc Discounted Cash Flow

Fully customizable DCF calculator online for Jazz Pharmaceuticals Plc.

Years

Calculation mode

= $22B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$1.1B	$1.2B	$1.4B	$1.5B	$1.6B	$1.8B	$1.9B	$2.1B	$2.3B	$2.6B	$2.8B	$28B
DCF		$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$11B
Value	$22B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	5%	25%	27%	30%	24%	24%	10%	-11%	-6%	11%	12%
ROA	-	15%	12%	10%	12%	10%	6%	1%	-1%	5%	5%
ROE	-	21%	21%	18%	16%	17%	7%	-8%	-7%	11%	11%

Good Net Margins (12.38%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	2.73	3.73	2.81	2.36	2.45	2.97	8.56	4.71	5.99	5.51
Debt over Equity	1.08	0.85	1.16	0.69	0.67	0.58	0.72	1.62	1.9	1.71	1.49
Growth Stability	-	-	-	100%	100%	100%	49%	-82%	-155%	-	-155%

Bad Debt/FCF ratio (5.51)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Neutral Debt/Equity ratio (1.49)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-155%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	13%	12%	9%	17%	14%	9%	31%	18%	5%	16%
Earnings YoY growth	-	475%	20%	23%	-8%	17%	-54%	-238%	-32%	-285%	3%
Equity YoY growth	-	17%	17%	45%	2%	13%	18%	8%	-22%	21%	3%
FCF YoY growth	-	34%	17%	14%	17%	-5%	20%	-15%	66%	-14%	11%